Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

Benzinga Newsdesk www.benzinga.com Negative 62.1%

Neg 62.1% Neu 0% Pos 0%

Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.

Comments

No comments yet. Be the first!